Camilo Jimenez, MD
Endocrinology, Diabetes & Metabolism · Houston, TXNPI 1275614372
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $11,832 of the $14,373 with a category attached, or 82.3%. 4 manufacturers reported payments, led by Progenics Pharmaceuticals, Inc. at 42.1% of the total. Reporting peaked in 2020 at $6,422 and has fallen 96.3% since, to $237 in 2024.
Across 13 payments — averaging $1105.63 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Progenics Pharmaceuticals, Inc.$6K
- Merck$5K
- HRA Pharma RARE Diseases$3K
- AstraZeneca$237
Across 26 payments — averaging $190,824 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Merck$4.9M
- Progenics Pharmaceuticals, Inc.$78K
- Exelixis Inc.$11K
What the payments were for
- Consulting fees$11,83282%
- Speaking & faculty fees$2372%
- Travel & lodging$2,09715%
- Food & beverage$2081%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Progenics Pharmaceuticals, Inc. | 7 | $6,049 |
| Merck | 4 | $4,688 |
| HRA Pharma RARE Diseases | 1 | $3,400 |
| AstraZeneca | 1 | $237 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$14,373 in reported general payments places this provider in the 75th percentile of 658 endocrinology, diabetes & metabolism providers in Texas.
See all endocrinology, diabetes & metabolism providers in Texas →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| LenvimaLenvatinib Mesylate | 12 | $276,895 |
| Teriparatide | 20 | $47,635 |
| Hydrocortisone | 15 | $795 |
| Levothyroxine Sodium | 42 | $527 |
| Doxazosin Mesylate | 13 | $499 |
Paid to pharmacies, not to this prescriber.
Other endocrinology, diabetes & metabolism in Houston
- Rocio HarbisonHouston$989K
- Andres SplenserHouston$923K
- Daniel TungHouston$753K
- Damaris VegaHouston$565K
- Steven PetakHouston$452K
- Amin JamalHouston$217K
- Laila TabatabaiHouston$207K
- Rakesh PatelHouston$187K
- Veena WatweHouston$157K
- Tiana ShiverHouston$136K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.